Global Secondary Antibodies Market Research Report 2023

Publication ID:

PB504235017

Publication Date:

April 4, 2023

Pages:

116

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Highlights
The global Secondary Antibodies market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Secondary Antibodies is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Secondary Antibodies is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Secondary Antibodies include Thermo Fisher Scientific (US), Jackson ImmunoResearch Laboratories (US), BD Biosciences (US), Santa Cruz Biotechnology (US), GE Healthcare (US), Sigma-Aldrich (US), Dako (US), LI-COR Biosciences (US) and SouthernBiotech (US), etc. in 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Secondary Antibodies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Secondary Antibodies.
The Secondary Antibodies market size, estimations, and forecasts are provided in terms of sales volume (MT) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Secondary Antibodies market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Secondary Antibodies manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Thermo Fisher Scientific (US)
Jackson ImmunoResearch Laboratories (US)
BD Biosciences (US)
Santa Cruz Biotechnology (US)
GE Healthcare (US)
Sigma-Aldrich (US)
Dako (US)
LI-COR Biosciences (US)
SouthernBiotech (US)
Vector Laboratories (US)
Bio-Rad (US)
eBioscience (US)
Cell Signaling Technology (US)
Dianova (Germany)
Abcam (UK)
EMD Millipore (US)
R&D Systems (US)
Rockland Immunochemicals (US)
Bethyl (US)
Kirkegaard & Perry Laboratories (US)
BioLegend (US)
Abbexa (UK)
Biorbyt (UK)
Acris Antibodies (Germany)
BioLogo (Germany)
Sino Biological (China)
Segment by Type
Men'
Animals'
Segment by Application
ELISA (Including Many HIV Tests)
Western Blot
Immunostaining
Immunohistochemistry
Immunocytochemistry
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Secondary Antibodies manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Secondary Antibodies in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Secondary Antibodies Market Overview
1.1 Product Overview and Scope of Secondary Antibodies
1.2 Secondary Antibodies Segment by Type
1.2.1 Global Secondary Antibodies Market Value Comparison by Type (2023-2029)
1.2.2 Men'
1.2.3 Animals'
1.3 Secondary Antibodies Segment by Application
1.3.1 Global Secondary Antibodies Market Value by Application: (2023-2029)
1.3.2 ELISA (Including Many HIV Tests)
1.3.3 Western Blot
1.3.4 Immunostaining
1.3.5 Immunohistochemistry
1.3.6 Immunocytochemistry
1.4 Global Secondary Antibodies Market Size Estimates and Forecasts
1.4.1 Global Secondary Antibodies Revenue 2018-2029
1.4.2 Global Secondary Antibodies Sales 2018-2029
1.4.3 Global Secondary Antibodies Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Secondary Antibodies Market Competition by Manufacturers
2.1 Global Secondary Antibodies Sales Market Share by Manufacturers (2018-2023)
2.2 Global Secondary Antibodies Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Secondary Antibodies Average Price by Manufacturers (2018-2023)
2.4 Global Secondary Antibodies Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Secondary Antibodies, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Secondary Antibodies, Product Type & Application
2.7 Secondary Antibodies Market Competitive Situation and Trends
2.7.1 Secondary Antibodies Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Secondary Antibodies Players Market Share by Revenue
2.7.3 Global Secondary Antibodies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Secondary Antibodies Retrospective Market Scenario by Region
3.1 Global Secondary Antibodies Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Secondary Antibodies Global Secondary Antibodies Sales by Region: 2018-2029
3.2.1 Global Secondary Antibodies Sales by Region: 2018-2023
3.2.2 Global Secondary Antibodies Sales by Region: 2024-2029
3.3 Global Secondary Antibodies Global Secondary Antibodies Revenue by Region: 2018-2029
3.3.1 Global Secondary Antibodies Revenue by Region: 2018-2023
3.3.2 Global Secondary Antibodies Revenue by Region: 2024-2029
3.4 North America Secondary Antibodies Market Facts & Figures by Country
3.4.1 North America Secondary Antibodies Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Secondary Antibodies Sales by Country (2018-2029)
3.4.3 North America Secondary Antibodies Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Secondary Antibodies Market Facts & Figures by Country
3.5.1 Europe Secondary Antibodies Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Secondary Antibodies Sales by Country (2018-2029)
3.5.3 Europe Secondary Antibodies Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Secondary Antibodies Market Facts & Figures by Country
3.6.1 Asia Pacific Secondary Antibodies Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Secondary Antibodies Sales by Country (2018-2029)
3.6.3 Asia Pacific Secondary Antibodies Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Secondary Antibodies Market Facts & Figures by Country
3.7.1 Latin America Secondary Antibodies Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Secondary Antibodies Sales by Country (2018-2029)
3.7.3 Latin America Secondary Antibodies Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Secondary Antibodies Market Facts & Figures by Country
3.8.1 Middle East and Africa Secondary Antibodies Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Secondary Antibodies Sales by Country (2018-2029)
3.8.3 Middle East and Africa Secondary Antibodies Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Secondary Antibodies Sales by Type (2018-2029)
4.1.1 Global Secondary Antibodies Sales by Type (2018-2023)
4.1.2 Global Secondary Antibodies Sales by Type (2024-2029)
4.1.3 Global Secondary Antibodies Sales Market Share by Type (2018-2029)
4.2 Global Secondary Antibodies Revenue by Type (2018-2029)
4.2.1 Global Secondary Antibodies Revenue by Type (2018-2023)
4.2.2 Global Secondary Antibodies Revenue by Type (2024-2029)
4.2.3 Global Secondary Antibodies Revenue Market Share by Type (2018-2029)
4.3 Global Secondary Antibodies Price by Type (2018-2029)
5 Segment by Application
5.1 Global Secondary Antibodies Sales by Application (2018-2029)
5.1.1 Global Secondary Antibodies Sales by Application (2018-2023)
5.1.2 Global Secondary Antibodies Sales by Application (2024-2029)
5.1.3 Global Secondary Antibodies Sales Market Share by Application (2018-2029)
5.2 Global Secondary Antibodies Revenue by Application (2018-2029)
5.2.1 Global Secondary Antibodies Revenue by Application (2018-2023)
5.2.2 Global Secondary Antibodies Revenue by Application (2024-2029)
5.2.3 Global Secondary Antibodies Revenue Market Share by Application (2018-2029)
5.3 Global Secondary Antibodies Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Thermo Fisher Scientific (US)
6.1.1 Thermo Fisher Scientific (US) Corporation Information
6.1.2 Thermo Fisher Scientific (US) Description and Business Overview
6.1.3 Thermo Fisher Scientific (US) Secondary Antibodies Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Thermo Fisher Scientific (US) Secondary Antibodies Product Portfolio
6.1.5 Thermo Fisher Scientific (US) Recent Developments/Updates
6.2 Jackson ImmunoResearch Laboratories (US)
6.2.1 Jackson ImmunoResearch Laboratories (US) Corporation Information
6.2.2 Jackson ImmunoResearch Laboratories (US) Description and Business Overview
6.2.3 Jackson ImmunoResearch Laboratories (US) Secondary Antibodies Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Jackson ImmunoResearch Laboratories (US) Secondary Antibodies Product Portfolio
6.2.5 Jackson ImmunoResearch Laboratories (US) Recent Developments/Updates
6.3 BD Biosciences (US)
6.3.1 BD Biosciences (US) Corporation Information
6.3.2 BD Biosciences (US) Description and Business Overview
6.3.3 BD Biosciences (US) Secondary Antibodies Sales, Revenue and Gross Margin (2018-2023)
6.3.4 BD Biosciences (US) Secondary Antibodies Product Portfolio
6.3.5 BD Biosciences (US) Recent Developments/Updates
6.4 Santa Cruz Biotechnology (US)
6.4.1 Santa Cruz Biotechnology (US) Corporation Information
6.4.2 Santa Cruz Biotechnology (US) Description and Business Overview
6.4.3 Santa Cruz Biotechnology (US) Secondary Antibodies Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Santa Cruz Biotechnology (US) Secondary Antibodies Product Portfolio
6.4.5 Santa Cruz Biotechnology (US) Recent Developments/Updates
6.5 GE Healthcare (US)
6.5.1 GE Healthcare (US) Corporation Information
6.5.2 GE Healthcare (US) Description and Business Overview
6.5.3 GE Healthcare (US) Secondary Antibodies Sales, Revenue and Gross Margin (2018-2023)
6.5.4 GE Healthcare (US) Secondary Antibodies Product Portfolio
6.5.5 GE Healthcare (US) Recent Developments/Updates
6.6 Sigma-Aldrich (US)
6.6.1 Sigma-Aldrich (US) Corporation Information
6.6.2 Sigma-Aldrich (US) Description and Business Overview
6.6.3 Sigma-Aldrich (US) Secondary Antibodies Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Sigma-Aldrich (US) Secondary Antibodies Product Portfolio
6.6.5 Sigma-Aldrich (US) Recent Developments/Updates
6.7 Dako (US)
6.6.1 Dako (US) Corporation Information
6.6.2 Dako (US) Description and Business Overview
6.6.3 Dako (US) Secondary Antibodies Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Dako (US) Secondary Antibodies Product Portfolio
6.7.5 Dako (US) Recent Developments/Updates
6.8 LI-COR Biosciences (US)
6.8.1 LI-COR Biosciences (US) Corporation Information
6.8.2 LI-COR Biosciences (US) Description and Business Overview
6.8.3 LI-COR Biosciences (US) Secondary Antibodies Sales, Revenue and Gross Margin (2018-2023)
6.8.4 LI-COR Biosciences (US) Secondary Antibodies Product Portfolio
6.8.5 LI-COR Biosciences (US) Recent Developments/Updates
6.9 SouthernBiotech (US)
6.9.1 SouthernBiotech (US) Corporation Information
6.9.2 SouthernBiotech (US) Description and Business Overview
6.9.3 SouthernBiotech (US) Secondary Antibodies Sales, Revenue and Gross Margin (2018-2023)
6.9.4 SouthernBiotech (US) Secondary Antibodies Product Portfolio
6.9.5 SouthernBiotech (US) Recent Developments/Updates
6.10 Vector Laboratories (US)
6.10.1 Vector Laboratories (US) Corporation Information
6.10.2 Vector Laboratories (US) Description and Business Overview
6.10.3 Vector Laboratories (US) Secondary Antibodies Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Vector Laboratories (US) Secondary Antibodies Product Portfolio
6.10.5 Vector Laboratories (US) Recent Developments/Updates
6.11 Bio-Rad (US)
6.11.1 Bio-Rad (US) Corporation Information
6.11.2 Bio-Rad (US) Secondary Antibodies Description and Business Overview
6.11.3 Bio-Rad (US) Secondary Antibodies Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Bio-Rad (US) Secondary Antibodies Product Portfolio
6.11.5 Bio-Rad (US) Recent Developments/Updates
6.12 eBioscience (US)
6.12.1 eBioscience (US) Corporation Information
6.12.2 eBioscience (US) Secondary Antibodies Description and Business Overview
6.12.3 eBioscience (US) Secondary Antibodies Sales, Revenue and Gross Margin (2018-2023)
6.12.4 eBioscience (US) Secondary Antibodies Product Portfolio
6.12.5 eBioscience (US) Recent Developments/Updates
6.13 Cell Signaling Technology (US)
6.13.1 Cell Signaling Technology (US) Corporation Information
6.13.2 Cell Signaling Technology (US) Secondary Antibodies Description and Business Overview
6.13.3 Cell Signaling Technology (US) Secondary Antibodies Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Cell Signaling Technology (US) Secondary Antibodies Product Portfolio
6.13.5 Cell Signaling Technology (US) Recent Developments/Updates
6.14 Dianova (Germany)
6.14.1 Dianova (Germany) Corporation Information
6.14.2 Dianova (Germany) Secondary Antibodies Description and Business Overview
6.14.3 Dianova (Germany) Secondary Antibodies Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Dianova (Germany) Secondary Antibodies Product Portfolio
6.14.5 Dianova (Germany) Recent Developments/Updates
6.15 Abcam (UK)
6.15.1 Abcam (UK) Corporation Information
6.15.2 Abcam (UK) Secondary Antibodies Description and Business Overview
6.15.3 Abcam (UK) Secondary Antibodies Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Abcam (UK) Secondary Antibodies Product Portfolio
6.15.5 Abcam (UK) Recent Developments/Updates
6.16 EMD Millipore (US)
6.16.1 EMD Millipore (US) Corporation Information
6.16.2 EMD Millipore (US) Secondary Antibodies Description and Business Overview
6.16.3 EMD Millipore (US) Secondary Antibodies Sales, Revenue and Gross Margin (2018-2023)
6.16.4 EMD Millipore (US) Secondary Antibodies Product Portfolio
6.16.5 EMD Millipore (US) Recent Developments/Updates
6.17 R&D Systems (US)
6.17.1 R&D Systems (US) Corporation Information
6.17.2 R&D Systems (US) Secondary Antibodies Description and Business Overview
6.17.3 R&D Systems (US) Secondary Antibodies Sales, Revenue and Gross Margin (2018-2023)
6.17.4 R&D Systems (US) Secondary Antibodies Product Portfolio
6.17.5 R&D Systems (US) Recent Developments/Updates
6.18 Rockland Immunochemicals (US)
6.18.1 Rockland Immunochemicals (US) Corporation Information
6.18.2 Rockland Immunochemicals (US) Secondary Antibodies Description and Business Overview
6.18.3 Rockland Immunochemicals (US) Secondary Antibodies Sales, Revenue and Gross Margin (2018-2023)
6.18.4 Rockland Immunochemicals (US) Secondary Antibodies Product Portfolio
6.18.5 Rockland Immunochemicals (US) Recent Developments/Updates
6.19 Bethyl (US)
6.19.1 Bethyl (US) Corporation Information
6.19.2 Bethyl (US) Secondary Antibodies Description and Business Overview
6.19.3 Bethyl (US) Secondary Antibodies Sales, Revenue and Gross Margin (2018-2023)
6.19.4 Bethyl (US) Secondary Antibodies Product Portfolio
6.19.5 Bethyl (US) Recent Developments/Updates
6.20 Kirkegaard & Perry Laboratories (US)
6.20.1 Kirkegaard & Perry Laboratories (US) Corporation Information
6.20.2 Kirkegaard & Perry Laboratories (US) Secondary Antibodies Description and Business Overview
6.20.3 Kirkegaard & Perry Laboratories (US) Secondary Antibodies Sales, Revenue and Gross Margin (2018-2023)
6.20.4 Kirkegaard & Perry Laboratories (US) Secondary Antibodies Product Portfolio
6.20.5 Kirkegaard & Perry Laboratories (US) Recent Developments/Updates
6.21 BioLegend (US)
6.21.1 BioLegend (US) Corporation Information
6.21.2 BioLegend (US) Secondary Antibodies Description and Business Overview
6.21.3 BioLegend (US) Secondary Antibodies Sales, Revenue and Gross Margin (2018-2023)
6.21.4 BioLegend (US) Secondary Antibodies Product Portfolio
6.21.5 BioLegend (US) Recent Developments/Updates
6.22 Abbexa (UK)
6.22.1 Abbexa (UK) Corporation Information
6.22.2 Abbexa (UK) Secondary Antibodies Description and Business Overview
6.22.3 Abbexa (UK) Secondary Antibodies Sales, Revenue and Gross Margin (2018-2023)
6.22.4 Abbexa (UK) Secondary Antibodies Product Portfolio
6.22.5 Abbexa (UK) Recent Developments/Updates
6.23 Biorbyt (UK)
6.23.1 Biorbyt (UK) Corporation Information
6.23.2 Biorbyt (UK) Secondary Antibodies Description and Business Overview
6.23.3 Biorbyt (UK) Secondary Antibodies Sales, Revenue and Gross Margin (2018-2023)
6.23.4 Biorbyt (UK) Secondary Antibodies Product Portfolio
6.23.5 Biorbyt (UK) Recent Developments/Updates
6.24 Acris Antibodies (Germany)
6.24.1 Acris Antibodies (Germany) Corporation Information
6.24.2 Acris Antibodies (Germany) Secondary Antibodies Description and Business Overview
6.24.3 Acris Antibodies (Germany) Secondary Antibodies Sales, Revenue and Gross Margin (2018-2023)
6.24.4 Acris Antibodies (Germany) Secondary Antibodies Product Portfolio
6.24.5 Acris Antibodies (Germany) Recent Developments/Updates
6.25 BioLogo (Germany)
6.25.1 BioLogo (Germany) Corporation Information
6.25.2 BioLogo (Germany) Secondary Antibodies Description and Business Overview
6.25.3 BioLogo (Germany) Secondary Antibodies Sales, Revenue and Gross Margin (2018-2023)
6.25.4 BioLogo (Germany) Secondary Antibodies Product Portfolio
6.25.5 BioLogo (Germany) Recent Developments/Updates
6.26 Sino Biological (China)
6.26.1 Sino Biological (China) Corporation Information
6.26.2 Sino Biological (China) Secondary Antibodies Description and Business Overview
6.26.3 Sino Biological (China) Secondary Antibodies Sales, Revenue and Gross Margin (2018-2023)
6.26.4 Sino Biological (China) Secondary Antibodies Product Portfolio
6.26.5 Sino Biological (China) Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Secondary Antibodies Industry Chain Analysis
7.2 Secondary Antibodies Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Secondary Antibodies Production Mode & Process
7.4 Secondary Antibodies Sales and Marketing
7.4.1 Secondary Antibodies Sales Channels
7.4.2 Secondary Antibodies Distributors
7.5 Secondary Antibodies Customers
8 Secondary Antibodies Market Dynamics
8.1 Secondary Antibodies Industry Trends
8.2 Secondary Antibodies Market Drivers
8.3 Secondary Antibodies Market Challenges
8.4 Secondary Antibodies Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Thermo Fisher Scientific (US)
Jackson ImmunoResearch Laboratories (US)
BD Biosciences (US)
Santa Cruz Biotechnology (US)
GE Healthcare (US)
Sigma-Aldrich (US)
Dako (US)
LI-COR Biosciences (US)
SouthernBiotech (US)
Vector Laboratories (US)
Bio-Rad (US)
eBioscience (US)
Cell Signaling Technology (US)
Dianova (Germany)
Abcam (UK)
EMD Millipore (US)
R&D Systems (US)
Rockland Immunochemicals (US)
Bethyl (US)
Kirkegaard & Perry Laboratories (US)
BioLegend (US)
Abbexa (UK)
Biorbyt (UK)
Acris Antibodies (Germany)
BioLogo (Germany)
Sino Biological (China)

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂